Kosacz Barbara 4

What Happened

• Barbara Kosacz, a director of LeonaBio, was granted a derivative award (reported as 28,000 shares acquired at $0.00) on June 23, 2026. The filing lists the transaction as an award/grant (code A) and shows $0 immediate cash value because these are an equity award/option subject to vesting and future conversion/exercise terms rather than a current purchase.

Key Details

• Transaction date: 2026-06-23; Form 4 filed: 2026-06-24 (timely; Form 4s are due within two business days).
• Reported amount: 28,000 shares (derivative award) at $0.00; total reported value: $0 (reflects grant status, not necessarily fair market value).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: The award vests on the earlier of (i) June 23, 2027, or (ii) the day before the next annual meeting of stockholders after June 22, 2026. The grant was made pursuant to the issuer's Outside Director Compensation Policy.
• Transaction code: A = Award/Grant (not a market purchase or sale).

Context

• This grant is a typical form of outside-director compensation and does not represent an immediate market purchase or sale. Because the award vests in the future, it does not provide immediate proceeds to the director and should be viewed as compensation rather than a direct signal of buying or selling activity.
• The filing does not indicate an exercise, sale, or tax-withholding action tied to these shares; any future exercise or sale would be reported separately.